Assessing the benefit–risk profile of newer glucose‐lowering drugs: A systematic review and network meta‐analysis of randomized outcome trials
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16147 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Huilin Tang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIDDK NIH HHS, Division of Diabetes, Endocrinology, and Metabolic Diseases.
Abstract (Originalsprache)
Aim
To comprehensively evaluate the benefits and risks of glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), dipeptidyl peptidase 4 inhibitors (DPP4i), and sodium‐glucose cotransporter 2 inhibitors (SGLT2i). Materials and Methods A systematic search of PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) from inception to November 2023 to identify randomized cardiovascular and kidney outcome trials that enrolled adults with type 2 diabetes, heart failure, or chronic kidney disease and compared DPP4i, GLP‐1RAs, or SGLT2i to placebo. Twenty‐one outcomes (e.g., major adverse cardiovascular events [MACE], stroke, and hospitalization for heart failure [HHF]) were assessed. Data were pooled using population‐averaged odds ratios (ORs) with 95% CIs.
Results
Twenty‐six trials enrolling 198 177 participants were included. GLP‐1RAs were most effective in lowering the risks of MACE (OR, 0.85, [95% CI, 0.79 to 0.92]) and stroke (0.84 [0.77, 0.91]), but increased the risk of thyroid cancer (1.58 [1.36, 2.50]). SGLT2i showed the greatest benefits in reducing the risk of HHF (0.68 [0.64, 0.73]) and improving composite renal outcomes (0.67 [0.58, 0.77]), but increased the risk of genital infections (3.11 [2.15, 4.50]). DPP4i were associated with a lower risk of certain psychiatric disorders, Parkinson's disease (0.54 [0.32, 0.92]), and amputation (0.70 [0.86, 0.93]), but an increased risk of neuropathy (1.10 [1.02, 1.18]) and pancreatitis (1.63 [1.40, 1.91]). The weighted origami plot suggested that GLP‐1RAs were more suitable for reducing macrovascular and microvascular outcomes, while DPP4i might be better for neurodegenerative diseases and cancer concerns.
Conclusions
Given the distinct benefit–risk profiles, the selection of glucose‐lowering drugs should be individualized based on patient characteristics and risk factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, Florida, USA.
- The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of Endocrinology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA.
- Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
- Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Huilin Tang, Pareeta Kotecha, Steven M Smith, Jingchuan Guo
Förderung
- NCI NIH HHS
- NIDDK NIH HHS
- Division of Diabetes, Endocrinology, and Metabolic Diseases
Zitieren
APA
Tang, H., Zhang, B., Lu, Y., Donahoo, W. T., Singh Ospina, N., Kotecha, P., Lu, Y., Tong, J., Smith, S. M., Rosenberg, E. I., Kimmel, S. E., Bian, J., Guo, J., & Chen, Y. (2025). Assessing the benefit–risk profile of newer glucose‐lowering drugs: A systematic review and network meta‐analysis of randomized outcome trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16147
Vancouver
Tang H, Zhang B, Lu Y, Donahoo WT, Singh Ospina N, Kotecha P, et al. Assessing the benefit–risk profile of newer glucose‐lowering drugs: A systematic review and network meta‐analysis of randomized outcome trials. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16147
BibTeX
@article{Tang2025,
author = {Tang, Huilin and Zhang, Bingyu and Lu, Yiwen and Donahoo, William T and Singh Ospina, Naykky and Kotecha, Pareeta and Lu, Ying and Tong, Jiayi and Smith, Steven M and Rosenberg, Eric I and Kimmel, Stephen E and Bian, Jiang and Guo, Jingchuan and Chen, Yong},
title = {Assessing the benefit–risk profile of newer glucose‐lowering drugs: A systematic review and network meta‐analysis of randomized outcome trials},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16147}
}
EUVIMED